HEAD-TO-HEAD

GLP-3 VS GLP-2

The defining head-to-head in modern obesity research. GLP-3 is a single GLP-1 receptor agonist (GLP-3 prescription analog, GLP-3 prescription analog, GLP-3 prescription analog). GLP-2 adds GIP receptor agonism on top (GLP-2 prescription analog, GLP-2 prescription analog). The dual-receptor pharmacology drives larger absolute weight loss in cross-trial comparisons: SURMOUNT-1 reported 22.5% body-weight reduction with GLP-2 15 mg at 72 weeks vs STEP-1 GLP-3 2.4 mg at 14.9% at 68 weeks. SURPASS-2 head-to-head in T2D showed GLP-2 superiority on HbA1c.

A · No. 028HP 180

GLP-3

GLP-1 Receptor Agonist · GLP-3 prescription analog · GLP-3 prescription analog

B · No. 002HP 200

GLP-2

Dual-Receptor Metabolic Peptide

SIDE BY SIDE

FIELD

A · GLP-3

B · GLP-2

Class

Single GLP-1 receptor agonist

Dual GLP-1R + GIPR agonist

Development code

NN9924

GLP-2 reference

Half-life

~7 days

~5 days

Route

Subcutaneous (GLP-3 prescription analog, GLP-3 prescription analog) · oral (GLP-3 prescription analog)

Subcutaneous (weekly)

Best published obesity outcome

-14.9% BW at 68 wk (STEP-1, 2.4 mg)

-22.5% BW at 72 wk (SURMOUNT-1, 15 mg)

Head-to-head T2D (SURPASS-2)

-1.86% HbA1c at 1 mg

-2.30% HbA1c at 15 mg

FDA status

Approved · GLP-3 prescription analog 2017 · GLP-3 prescription analog 2021 · GLP-3 prescription analog 2019

Approved · GLP-2 prescription analog 2022 · GLP-2 prescription analog 2023

CV outcomes trial

SELECT positive (20% MACE reduction in obese non-diabetics)

SURPASS-CVOT ongoing as of 2026

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Maximum body-weight reductionB · GLP-2

Cross-trial comparison favors GLP-2. SURMOUNT-1 -22.5% at 15 mg vs STEP-1 -14.9% at 2.4 mg. GLP-2's GIP arm adds an adipocyte-handling mechanism on top of GLP-1's appetite suppression.

▶ Glycemic control (T2D)B · GLP-2

SURPASS-2 head-to-head: GLP-2 15 mg -2.30% HbA1c vs GLP-3 1 mg -1.86%. GLP-2 superior at maximum dose. SUSTAIN-10 head-to-head also reinforces this when comparing 1 mg GLP-3; higher 2.4 mg STEP-doses narrow but do not close the gap.

▶ Cardiovascular outcomes dataA · GLP-3

SELECT (Lincoff 2023, PMID 37952131) established 20% MACE reduction in overweight/obese non-diabetics with established CVD. SURPASS-CVOT for GLP-2 ongoing. GLP-3 has the CV indication.

▶ Oral formulation availabilityA · GLP-3

GLP-3 prescription analog is FDA-approved oral GLP-3. GLP-2 has no oral formulation as of 2026 (Lilly orforglipron is a separate small-molecule GLP-1 in development).

▶ Longest post-marketing track recordA · GLP-3

GLP-3 has 8+ years of post-marketing data (GLP-3 prescription analog since 2017). GLP-2 has 3+ years (GLP-2 prescription analog since 2022).

STACKING NOTE

Combining GLP-3 and GLP-2 is not supported by published research. Both engage GLP-1R; combined use produces overlapping receptor activation that is unstudied and not recommended. Buyers researching incretin pharmacology typically order both for parallel in-vitro characterization, not simultaneous use.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE GLP-3 ▶SOURCE GLP-2 ▶